Savara (NASDAQ:SVRA) Given “Market Outperform” Rating at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Savara (NASDAQ:SVRA) in a research note published on Thursday morning, Benzinga reports. JMP Securities currently has a $8.00 price objective on the stock.

Separately, Piper Sandler lifted their price target on shares of Savara from $7.00 to $16.00 and gave the stock an overweight rating in a research report on Monday, March 4th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of Buy and an average price target of $8.20.

Savara Price Performance

NASDAQ SVRA opened at $4.79 on Thursday. Savara has a 12 month low of $1.76 and a 12 month high of $5.70. The company has a debt-to-equity ratio of 0.19, a current ratio of 15.66 and a quick ratio of 15.66. The firm has a market capitalization of $661.74 million, a PE ratio of -14.52 and a beta of 0.77. The company’s 50 day simple moving average is $4.97 and its 200 day simple moving average is $4.39.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. As a group, equities research analysts forecast that Savara will post -0.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada acquired a new position in Savara in the second quarter worth approximately $25,000. AJOVista LLC acquired a new position in Savara in the 4th quarter worth approximately $40,000. Alliancebernstein L.P. acquired a new position in Savara in the 2nd quarter worth approximately $38,000. XTX Topco Ltd acquired a new position in Savara in the 2nd quarter worth approximately $40,000. Finally, Principal Financial Group Inc. acquired a new position in Savara in the 3rd quarter worth approximately $48,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.